| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | -26.38% | Morgan Stanley | $11 → $12 | Maintains | Underweight |
| 11/02/2023 | -32.52% | Morgan Stanley | $10 → $11 | Maintains | Underweight |
| 10/11/2023 | -38.65% | Morgan Stanley | $15 → $10 | Maintains | Underweight |
| 09/28/2023 | -44.79% | BMO Capital | $8 → $9 | Maintains | Underperform |
| 08/04/2023 | 4.29% | Piper Sandler | $18 → $17 | Maintains | Neutral |
| 08/03/2023 | -7.98% | Morgan Stanley | $14 → $15 | Maintains | Underweight |
| 07/12/2023 | 145.4% | JMP Securities | → $40 | Reiterates | Market Outperform → Market Outperform |
| 06/20/2023 | -14.11% | Morgan Stanley | → $14 | Initiates Coverage On | → Underweight |
| 05/09/2023 | 4.29% | Barclays | $16 → $17 | Maintains | Equal-Weight |
| 05/05/2023 | 10.43% | Piper Sandler | → $18 | Reiterates | → Neutral |
| 05/04/2023 | -26.38% | B of A Securities | $14 → $12 | Maintains | Underperform |
| 05/04/2023 | 145.4% | JMP Securities | → $40 | Reiterates | → Market Outperform |
| 04/18/2023 | 145.4% | JMP Securities | → $40 | Reiterates | → Market Outperform |
| 04/10/2023 | -29.45% | Jefferies | $13 → $11.5 | Maintains | Underperform |
| 02/24/2023 | -1.84% | Barclays | $18 → $16 | Maintains | Equal-Weight |
| 02/24/2023 | 10.43% | Piper Sandler | $19 → $18 | Maintains | Neutral |
| 01/20/2023 | -38.65% | BMO Capital | → $10 | Initiates Coverage On | → Underperform |
| 01/18/2023 | 16.56% | Piper Sandler | $20 → $19 | Maintains | Neutral |
| 11/17/2022 | 47.24% | Keefe, Bruyette & Woods | → $24 | Initiates Coverage On | → Market Perform |
| 11/10/2022 | 10.43% | Barclays | $28 → $18 | Maintains | Equal-Weight |
| 11/10/2022 | 22.7% | Piper Sandler | $25 → $20 | Maintains | Neutral |
| 08/10/2022 | 71.78% | Barclays | $20 → $28 | Maintains | Equal-Weight |
| 08/10/2022 | 53.37% | Piper Sandler | $20 → $25 | Maintains | Neutral |
| 07/18/2022 | 22.7% | Piper Sandler | $24 → $20 | Downgrades | Overweight → Neutral |
| 05/13/2022 | 22.7% | Barclays | $22 → $20 | Maintains | Equal-Weight |
| 05/11/2022 | 84.05% | Oppenheimer | $45 → $30 | Maintains | Outperform |
| 05/11/2022 | 145.4% | JMP Securities | $95 → $40 | Maintains | Market Outperform |
| 05/11/2022 | 47.24% | Piper Sandler | $32 → $24 | Maintains | Overweight |
| 03/04/2022 | 71.78% | Morgan Stanley | $74 → $28 | Maintains | Equal-Weight |
| 02/25/2022 | 176.07% | Oppenheimer | $85 → $45 | Maintains | Outperform |
| 02/25/2022 | 96.32% | Piper Sandler | $54 → $32 | Maintains | Overweight |
| 01/13/2022 | 231.29% | Piper Sandler | $84 → $54 | Maintains | Overweight |
| 01/06/2022 | 163.8% | Barclays | $62 → $43 | Maintains | Equal-Weight |
| 11/19/2021 | 200.61% | Jefferies | → $49 | Initiates Coverage On | → Underperform |
| 11/10/2021 | 482.82% | JMP Securities | $130 → $95 | Maintains | Market Outperform |
| 11/10/2021 | 421.47% | Oppenheimer | $95 → $85 | Maintains | Outperform |
| 11/10/2021 | 280.37% | Barclays | $68 → $62 | Maintains | Equal-Weight |
| 10/19/2021 | 317.18% | Barclays | $80 → $68 | Maintains | Equal-Weight |
| 10/15/2021 | 353.99% | Morgan Stanley | $90 → $74 | Maintains | Equal-Weight |
| 08/17/2021 | 225.15% | Wolfe Research | → $53 | Initiates Coverage On | → Underperform |
| 08/06/2021 | 482.82% | Oppenheimer | $85 → $95 | Maintains | Outperform |
| 08/06/2021 | 501.23% | Piper Sandler | $103 → $98 | Maintains | Overweight |
| 05/13/2021 | 335.58% | Barclays | $101 → $71 | Maintains | Equal-Weight |
| 03/09/2021 | 77.91% | B of A Securities | → $29 | Initiates Coverage On | → Underperform |
| 03/08/2021 | 574.85% | Oppenheimer | → $110 | Upgrades | Perform → Outperform |
| 03/03/2021 | 697.55% | JMP Securities | $105 → $130 | Maintains | Outperform |
| 01/21/2021 | 900% | Piper Sandler | $105 → $163 | Maintains | Overweight |
| 01/12/2021 | 452.15% | Morgan Stanley | $70 → $90 | Maintains | Equal-Weight |
| 12/16/2020 | 544.17% | Piper Sandler | $71 → $105 | Maintains | Overweight |
| 11/12/2020 | 335.58% | Piper Sandler | $63 → $71 | Maintains | Overweight |
| 11/02/2020 | 286.5% | Piper Sandler | → $63 | Initiates Coverage On | → Overweight |
| 10/15/2020 | 243.56% | Credit Suisse | → $56 | Initiates Coverage On | → Underperform |
| 08/14/2020 | 329.45% | Morgan Stanley | $91 → $70 | Maintains | Equal-Weight |
| 07/27/2020 | 169.94% | Goldman Sachs | → $44 | Initiates Coverage On | → Sell |
| 07/27/2020 | 458.28% | Morgan Stanley | → $91 | Initiates Coverage On | → Equal-Weight |
| 07/27/2020 | 409.2% | Barclays | → $83 | Initiates Coverage On | → Equal-Weight |
| 07/27/2020 | 544.17% | JMP Securities | → $105 | Initiates Coverage On | → Market Outperform |
What is the target price for Lemonade (LMND)?
The latest price target for Lemonade (NYSE: LMND) was reported by Morgan Stanley on November 7, 2023. The analyst firm set a price target for $12.00 expecting LMND to fall to within 12 months (a possible -26.38% downside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lemonade (LMND)?
The latest analyst rating for Lemonade (NYSE: LMND) was provided by Morgan Stanley, and Lemonade maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Lemonade (LMND)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lemonade, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lemonade was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Lemonade (LMND) correct?
While ratings are subjective and will change, the latest Lemonade (LMND) rating was a maintained with a price target of $11.00 to $12.00. The current price Lemonade (LMND) is trading at is $16.30, which is out of the analyst's predicted range.